Alzheimer Disease Therapeutic Pipeline Market Overview, Drugs & Key Players Profiles H2 2014

Share Article adds Alzheimer’s disease – Pipeline Review, H2 2014 market research report of 1141 pages to the Alzheimer’s disease and Alzheimer drugs industry research collection of its business intelligence library.

Alzheimer disease Therapeutic Pipeline Market

Alzheimer disease Therapeutic Pipeline Market

The “Alzheimer’s Disease – Pipeline Review, H2 2014" market research report provides comprehensive information on the therapeutic development for Alzheimer’s disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer’s disease and special features on late-stage and discontinued projects. Alzheimer's ailment (AD), otherwise called Alzheimer sickness, is the most widely recognized type of dementia. Frequently, Alzheimer's illness is diagnosed in individuals in excess of 65 years old, despite the fact that the less-pervasive early-onset Alzheimer's can happen in much more youthful individuals. Complete Report is Available @ .

Companies discussed in this Alzheimer’s Disease therapy Pipeline market report include AB Science, AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Accera, Inc., Acelot, Inc., Acumen Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., Addex Therapeutics Ltd, Advanced Cell Technology, Inc., Affichem AFFiRiS AG, Alector LLC, ALSP, Inc., AlzeCure Discovery AB, Alzhyme Pty Ltd, Alzinova AB, AlzProtect SAS, Amarantus Bioscience Holdings, Inc., Amgen Inc., Anavex Life Sciences Corp., Angita B.V., Apodemus AB, Araclon Biotech, S.L., Archer Pharmaceuticals, Inc., ArmaGen Technologies, Inc., Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Ausio Pharmaceuticals, LLC, Avergen Ltd, Avineuro Pharmaceuticals, Inc., Axerion Therapeutics, Inc., Axon Neuroscience SE, Axxam SpA, Azevan Pharmaceuticals, Inc., BioArctic Neuroscience AB, biOasis Technologies Inc., Biogen Idec Inc., Biomar Microbial Technologies, Bionature E.A. Ltd., Bionure Farma, S.L., Biotie Therapies Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, BSIM2, CalAsia Pharmaceuticals, Inc., Cardax Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., CHA Bio & Diostech Co., Ltd., Chase Pharmaceuticals Corporation, Clera Inc., Cognition Therapeutics, Inc., Cognosci, Inc., CoLucid Pharmaceuticals, Inc., CoMentis, Inc., Cortica Neurosciences, Inc., Critical Outcome Technologies Inc., CrystalGenomics, Inc., D-Pharm Ltd., Daewoong Pharmaceutical Co., Ltd., Delenex Therapeutics AG, DermaXon, LLC, Domain Therapeutics SA, Echo Pharmaceuticals B.V., Eisai Co., Ltd., Eli Lilly and Company, EncephRx, Inc., EndoCeutics, Inc., Epigen Biosciences, Inc., Eucalyptus Ltd., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Galantos Pharma GmbH, Genentech, Inc., Genervon Biopharmaceuticals, LLC, GlaxoSmithKline plc, GliaCure Inc., Grifols, S.A., H. Lundbeck A/S, High Point Pharmaceuticals, LLC, Humanetics Corporation, Ichor Medical Systems, Inc., Icure Pharmaceutical Inc., IMMD Inc., Immunome Inc., ImStar Therapeutics Inc., Inovio Pharmaceuticals, Inc., Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Io Therapeutics, Inc., Iproteos S.L., Janssen Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Johnson & Johnson, and K-Stemcell Co., Ltd. Order a copy of this report at .

Alzheimer's disease is categorized as a neurodegenerative problem, the cause and development of which are poorly recognized. The ailment process seems to be associated with plagues and troubles in the mind. No therapies stop or opposite its development, though some can reduce signs. As of 2014, more than 1,500 medical studies have been or are being performed to analyze various therapies in AD. Psychological activation, exercise, and a healthy diet have been recommended as ways to wait intellectual signs (though not mind pathology) in healthy mature individuals, but there is no definite proof assisting an impact.

Reasons to buy the report "Sepsis – Pipeline Review, H2 2014": Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies. Identify and understand important and diverse types of therapeutics under development for Rabies. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Explore more reports on Alzheimer Drugs industry at .

About Us: is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website